Based on the SCS macrophage depletion duration (Figure 4), we injected PBS-L or CLL 7 days prior to the tumor implantation, at the time of the implantation, and weekly after the implantation to maintain CD169+ macrophage depletion throughout tumor growth. The gene discussed is SIGLEC1; the disease is neoplasm.